ArticleWorld journal of gastroenterology2003
Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors.
Article in World journal of gastroenterology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Endoscopic resection: A novel approach for treating oesophageal gastrointestinal stromal tumours.World journal of gastrointestinal endoscopy · 2025Article
- Endoscopic treatment outcome of oesophageal gastrointestinal stromal tumours.World journal of gastroenterology · 2025Article
- A multidisciplinary approach in the diagnostic challenge of GIST.Experimental and therapeutic medicine · 2021Article
- Is the Surgical Margin in Gastrointestinal Stromal Tumors Different?Visceral medicine · 2018Review
- GEIS 2013 guidelines for gastrointestinal sarcomas (GIST).Cancer chemotherapy and pharmacology · 2014Review
- Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.Journal of the American College of Surgeons · 2012Article
- Surgical margin status and prognosis of gastrointestinal stromal tumor.World journal of surgery · 2008Article
- Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.Medical oncology (Northwood, London, England) · 2008Article
- Stromal tumour of the stomach.Canadian journal of surgery. Journal canadien de chirurgie · 2007Article
- Fibromyxoma of the small bowel: a review.Digestive diseases and sciences · 2007Review
- A novel gain of function mutant in C-kit gene and its tumorigenesis in nude mice.World journal of gastroenterology · 2005Article
- Localized intra-abdominal fibromatosis of the small bowel mimicking a gastrointestinal stromal tumor: a case report.World journal of gastroenterology · 2005Article
- Angiographic findings of gastrointestinal stromal tumor.World journal of gastroenterology · 2004Article
- Neurofibromatosis with gastrointestinal stromal tumors: insights into the association.Digestive diseases and sciences · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the incidence of CD117-positive immunohistochemical staining in previously diagnosed gastrointestinal (GI) tract stromal tumors (GIST) and to analyze the tumors' clinical manifestations and prognostic factors.
methodsWe retrospectively reviewed 91 cases with a previous diagnosis of GI stromal tumor, leiomyoma, or leiomyosarcoma. Tissue samples were assessed with CD117, CD34, SMA and S100 immunohistochemical staining. Clinical and pathological characteristics were analyzed for prognostic factors.
resultsCD117 was positive in 81 (89%) of 91 tissue samples. There were 59 cases (72.8%) positive for CD34, 13 (16%) positive for SMA, and 12 (14.8%) positive for S100. There was no gender difference in patients with CD117-positive GIST. Their mean age was 65 years. There were 44 (54%) tumors located in the stomach and 29 (36%) in the small intestine. The most frequent presenting symptoms were abdominal pain and GI bleeding. The mean tumor size was 7.5 +/- 5.7 cm. There were 35 cases (43.2%) with tumors >5 cm. The tumor size correlated significantly with tumor mitotic count and resectability. Tumor size, mitotic count, and resectability correlated significantly with tumor recurrence and survival. There was recurrent disease in 39% of our patients, and their mean survival after recurrence was 16.6 months. Most recurrences were at the primary site or metastatic to the liver. Twenty-six percent of our patients died of their disease.
conclusionTraditional histologic criteria are not specific enough to diagnose GIST. This diagnosis must be confirmed with CD117 immunohistochemical staining. Prognosis is dependent on tumor size, mitotic count, and resectability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.